Aurora Cannabis (ACB) Income from Continuing Operations (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly Income from Continuing Operations of 40001307.44 for Q1 2026, down 682.02% year-over-year from 6872798.78 in Q1 2025, and down 3154.05% quarter-over-quarter from 1229279.24 in Q4 2025.
Aurora Cannabis (ACB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Income from Continuing Operations for 10 consecutive years, with 40001307.44 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 682.02% year-over-year to 40001307.44; the TTM figure through Mar 2026 stood at 89085295.85 (down 525.3% YoY), while the FY2026 annual figure was 89138832.99, down 558.09% from the prior year.
- Income from Continuing Operations eased to 40001307.44 in Q1 2026 per ACB's latest filing, from 1229279.24 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 32596636.09 in Q1 2024 and bottomed at 4711000000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 477428923.76 across 5 years, with a median of 23927354.59 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 5307.3% — and 2024, when it soared 261.68%.
- Aurora Cannabis' Income from Continuing Operations stood at 538181388.66 in 2022, then jumped by 97.68% to 12511920.9 in 2023, then surged by 261.68% to 20229644.21 in 2024, then plunged by 106.08% to 1229279.24 in 2025, then tumbled by 3154.05% to 40001307.44 in 2026.
- Business Quant data shows ACB's Income from Continuing Operations at 40001307.44 in Q1 2026, 1229279.24 in Q4 2025, and 33789254.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aurora Cannabis | 233.45 Mn | 161.14 Mn | 25.75 Mn | -2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.00 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | -33.79 Mn |
| Jun 30, 2025 | -14.07 Mn |
| Mar 31, 2025 | -5.12 Mn |
| Dec 31, 2024 | 20.23 Mn |
| Sep 30, 2024 | 977,893.25 |
| Jun 30, 2024 | 4.85 Mn |
| Mar 31, 2024 | 32.60 Mn |
| Dec 31, 2023 | -12.51 Mn |
| Sep 30, 2023 | -53.58 Mn |
| Jun 30, 2023 | -4.71 Bn |
| Dec 31, 2022 | -538.18 Mn |
| Sep 30, 2022 | -511.99 Mn |
| Jun 30, 2022 | -485.36 Mn |
| Mar 31, 2022 | -1.29 Bn |
| Dec 31, 2021 | -59.84 Mn |
| Sep 30, 2021 | -9.47 Mn |
| Jun 30, 2021 | -96.69 Mn |
| Mar 31, 2021 | -130.68 Mn |